Latest News

  • Alkermes Statement on National Academies of Sciences, Engineering, and Medicine Report on Medications for Opioid Use Disorder Read More
  • Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 39th Annual Health Care Conference Read More
  • Alkermes Initiates Clinical Study of ALKS 4230 Administered Subcutaneously in Patients With Advanced Solid Tumors Read More

Investors

ALKS investor relations
Learn more Learn More

Pipeline

patient focused CNS disorder treatments
See Our Approach See Our Approach

Working at Alkermes

career opportunities at Alkermes
Working at Alkermes Join Our Team